Immunome Presents Compelling Preclinical Data on Anti-IL-38 Antibody Program at the American Association for Cancer Research NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
News
Annovis Bio Announces Positive Phase Two Efficacy Data for Treatment of Parkinson’s Disease
Data Shows Statistically Significant Improvements in Speed and Motor Function in PD Patients
Annovis Bio to Request Meeting with FDA on Next Steps in Clinical Development
Investor Conference Call to be Hosted Tuesday, October 5th, 2021, at 9:00 am ET
Renovacor Announces the Appointment of Kumar Dhanasekharan, Ph.D., as Senior Vice President of Technical Operations
Dr. Dhanasekharan joins Renovacor with extensive experience overseeing development, manufacturing and supply operations for biologics including AAV gene therapies
Halo Labs Launches the Aura GT™ for Gene Therapy Product Quality
Aura GT is the first system specifically designed to quantify capsid aggregates and identify the mechanism of aggregation
BioAdvance Announces ~$7M in Recent Investments and Leadership Transition
Barbara Schilberg retiring as Managing Director and CEO;
Shahram Hejazi, Ph.D., appointed as Managing Director and CEO
Renovacor Announces the Appointment of Jordan Shin, M.D., Ph.D., as Senior Vice President of Clinical Development and Translational Science
Dr. Shin to help advance REN-001 into the clinic by leveraging nearly two decades of expertise in clinical development, academic research and medical practice
Syneos Health and Ride Health Partner to Improve Clinical Trial Recruitment and Retention
Partnership Creates a More Patient-centric Travel Experience, Drives Adherence and Advances Diversity and Inclusion in Clinical Research
Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes SARS-CoV-2 Lambda and Delta Plus Variants in Pre-clinical Testing
– IMM-BCP-01 already shown to neutralize all other Centers for Disease Control (CDC) variants of concern in pre-clinical testing
Renovacor Inc. Closes Its Business Combination with Chardan Healthcare Acquisition 2 Corp. and Will Begin Trading on the New York Stock Exchange
Common stock and warrants of the combined company, renamed Renovacor, Inc., will commence trading on September 3, 2021 on the NYSE under ticker symbols “RCOR” and “RCOR.WS”, respectively.
Gross proceeds from the transaction totaled approximately $95.1 million.
Phrase Health Awarded Phase 2 NIH Grant To Scale Quality Improvement Platform
The $1.7 million Phase 2 STTR grant expands upon the quality improvement and informatics cloud-based software developed by the company